Promise Proteomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Promise Proteomics is a commercial-stage diagnostics and tools company focused on the proteomics and oncology sectors. Its core offering is the mAbXmise kit, a CE-IVD marked in-vitro diagnostic device for quantifying therapeutic monoclonal antibodies using liquid chromatography-mass spectrometry (LC-MS). The company also provides stable isotope-labeled (SIL) proteins for research, custom protein production services, and diagnostic kits for CBRN (chemical, biological, radiological, nuclear) threats. With ISO certification and European regulatory clearance for its main product, Promise Proteomics is positioned as a provider of robust quantification solutions for clinical laboratories and bioanalytical scientists.

Oncology

Technology Platform

Mass spectrometry-based protein quantification platform utilizing Liquid Chromatography-Mass Spectrometry (LC-MS) and proprietary stable isotope-labeled (SIL) internal standards for absolute quantification of therapeutic monoclonal antibodies and other proteins in biological samples.

Opportunities

The rapid growth of monoclonal antibody therapies creates a large and growing need for precise therapeutic drug monitoring (TDM) in clinical practice.

The shift from immunoassays to more specific mass spectrometry methods in clinical labs presents a major market transition that Promise Proteomics' standardized kits are designed to capture.

Further opportunities exist in expanding the test menu, entering larger regulatory markets like the US, and leveraging the platform for other protein biomarkers.

Risk Factors

Key risks include slow adoption of LC-MS technology in routine clinical labs due to cost and complexity, competition from large diagnostic companies and alternative technologies, and the significant regulatory hurdles required to expand sales beyond Europe.

The company's growth is also tied to the concentration of its business on the mAbXmise product line.

Competitive Landscape

Promise Proteomics competes in the niche of MS-based protein quantification. Competitors include large mass spectrometry instrument vendors (e.g., Sciex, Thermo Fisher, Waters) who offer complementary reagents and workflows, other specialized proteomics companies providing SIL peptides and assay services, and traditional IVD companies using immunoassays for drug monitoring. Its key differentiator is the CE-IVD marked, kit-based format designed specifically for clinical lab use.

More companies in Diagnostics & Precision Medicine →More companies in France →